Earnings Scheduled For May 13, 2014

Related FOSL Stocks To Watch For May 13, 2014 Will Fossil Inc. (FOSL) Beat Earnings Estimates? - Analyst Blog

CST Brands (NYSE: CST) is expected to report its Q1 earnings at $0.19 per share on revenue of $3.07 billion.

Fossil Group (NASDAQ: FOSL) is projected to post its Q1 earnings at $1.17 per share on revenue of $771.60 million.

Take-Two Interactive Software (NASDAQ: TTWO) is expected to post its Q4 earnings at $0.10 per share on revenue of $202.51 million.

CTI Industries (NASDAQ: CTIB) is estimated to report its Q1 earnings at $0.02 per share on revenue of $15.75 million.

URS (NYSE: URS) is projected to post its Q1 earnings at $0.68 per share on revenue of $2.68 billion.

LATAM Airlines Group SA (NYSE: LFL) is expected to post its Q1 earnings at $0.20 per share on revenue of $3.42 billion.

Gladstone Investment (NASDAQ: GAIN) is projected to post its Q4 earnings at $0.17 per share on revenue of $8.90 million.

First Horizon National (NYSE: FHN) is expected to report its Q2 earnings at $0.17 per share on revenue of $286.98 million.

Synacor (NASDAQ: SYNC) is estimated to post a Q1 loss at $0.05 per share on revenue of $24.53 million.

Diana Containerships (NASDAQ: DCIX) is projected to report its Q1 earnings at $0.01 per share on revenue of $13.22 million.

Intrawest Resorts Holdings (NYSE: SNOW) is expected to post its Q3 earnings at $2.69 per share on revenue of $294.89 million.

Cosan (NYSE: CZZ) is estimated to post its Q1 earnings at $0.16 per share.

ViaSat (NASDAQ: VSAT) is projected to post its Q4 earnings at $0.11 per share on revenue of $348.98 million.

Biodel (NASDAQ: BIOD) is expected to post a Q1 loss at $0.24 per share.

First Majestic Silver (NYSE: AG) is estimated to post its Q1 earnings at $0.10 per share on revenue of $63.35 million.

Dr. Reddy's Laboratories (NYSE: RDY) is expected to report its Q4 earnings at $0.52 per share.

YuMe (NYSE: YUME) is estimated to post a Q1 loss at $0.15 per share on revenue of $35.36 million.

Vertex Energy (NASDAQ: VTNR) is projected to report its Q1 earnings at $0.03 per share on revenue of $42.48 million.

Hot Retail Stocks To Own Right Now

Idera Pharmaceuticals (NASDAQ: IDRA) is estimated to report a Q1 loss at $0.08 per share on revenue of $3.00 thousand.

USA Technologies (NASDAQ: USAT) is projected to report its Q3 earnings at $0.00 per share on revenue of $10.63 million.

P&F Industries (NASDAQ: PFIN) is expected to report its quarterly results.

INSYS Therapeutics (NASDAQ: INSY) is projected to report its Q1 earnings at $0.28 per share on revenue of $45.63 million.

Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  Most Popular Earnings Expectations For The Week Of May 12: Wal-Mart, Deere, Cisco And More JPMorgan Comments on J.C. Penney In The Run-Up To Q1 Earnings Report 5 Companies Apple Could Buy Instead Of Beats Short Sellers Load Up On Pandora and Zynga (GRPN, P, ZNGA) UPDATE: MLV & Co Reiterates On Keryx Biopharmaceuticals On Increased Risk Surges In Biotech Short Interest (INCY, PCYC, RGEN) Related Articles (BIOD + AG) Earnings Scheduled For May 13, 2014 Benzinga Weekly Preview: Several Large Retailers Set To Report Biodel, HEC Pharm Ink Deal - Analyst Blog Abbott Labs Tops Earnings, Misses Sales Est - Analyst Blog

5 Stocks Insiders Love Right Now

DELAFIELD, Wis. (Stockpickr) -- Corporate insiders sell their own companies' stock for a number of reasons.

>>5 Stocks Set to Soar on Bullish Earnings

They might need the cash for a big personal purchase such as a new house or yacht, or they might need the cash to fund a charity. Sometimes they sell as part of a planned selling program that they have put in place for diversification purposes, which allows them to sell stock in stages instead of selling all at one price.

Other times they sell because they think their stock is overvalued and the risk/reward is no longer attractive. Some even dump their own stock because they have inside knowledge that a competitor is eating their lunch and stealing market share.

But insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.

>>5 Utility Sector Trades to Beat Wall Street



The key word in that last statement is "think." Just because a corporate insider thinks his or her stock is going to trade higher, that doesn't mean it will play out that way. Insiders can have all the conviction in the world that their stock is a buy, but if the market doesn't agree with them, the stock could end up going nowhere. Also, I say "usually" because sometimes insiders are loaned money by the company to buy their own stock. Those loans are often sweetheart deals and shouldn't be viewed as organic insider buying.

At the end of the day, it's large institutional money managers running big mutual funds and hedge funds that drive stock prices, not insiders. That said, many of these savvy stock operators will follow insider buying activity when they agree with the insider that the stock is undervalued and has upside potential. This is why it's so important to always be monitoring insider activity, but it's twice as important to make sure the trend of the stock coincides with the insider buying.

>>Big Funds Love This Small Stock -- Should You?

Recently, a number of companies' corporate insiders have bought large amounts of stock. These insiders are finding some value in the market, which warrants a closer look at these stocks. Here's a look five stocks whose insiders have been doing some big buying per SEC filings.

BJ's Restaurants

One restaurant operator that insiders are loading up on here is BJ's Restaurants (BJRI), which offer pizzas, beers, appetizers, entrees, pastas, sandwiches, salads and desserts. Insiders are buying this stock into strength, since shares are up 12% over the last six months.

BJ's Restaurants has a market cap of $926 million and an enterprise value of $904 million. This stock trades at a premium valuation, with a trailing price-to-earnings of 44 and a forward price-to-earnings of 36. Its estimated growth rate for this year is -19%, and for next year it's pegged at 39%. This is a cash-rich company, since the total cash position on its balance sheet is $30.98 million and its total debt is zero.

A officer just bought 89,072 shares, or about $2.91 million worth of stock, at $32.70 per share. That same officer also just bought 242,713 shares, or about $8 million worth of stock, at $32.99 per share.

From a technical perspective, BJRI is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock is spiking higher here right above its 200-day moving average of $31.08 a share. That move is starting to push shares of BJRI within range of triggering a big breakout trade.

If you're bullish on BJRI, then I would look for long-biased trades as long as this stock is trending above its 50-day at $30.45 and then once breaks out above some near-term overhead resistance levels at $33.44 to $35.35 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 641,837 shares. If that breakout kicks off soon, then BJRI will set up to re-test or possibly take out its next major overhead resistance level at $40.99 a share.

Ameresco

A renewable energy player that insiders are active in here is Ameresco (AMRC), which develops, designs, engineers and installs projects that reduce the energy and operations and maintenance costs of facilities. Insiders are buying this stock into major weakness, since shares are down by 25% so far in 2014.

Ameresco has a market cap of $328 million and an enterprise value of $481 million. This stock trades at a premium valuation, with a trailing price-to-earnings of 143 and a forward price-to-earnings of 25. Its estimated growth rate for this year is 260%, and for next year it's pegged at 55.6%. This is not a cash-rich company, since the total cash position on its balance sheet is $17.17 million and its total debt is $164.76 million.

The CEO just bought 96,675 shares, or about $719,000 worth of stock, at $7.22 per share.

From a technical perspective, AMRC is currently trending below both its 50-day and 200-day moving averages, which is bearish. This stock has been downtrending badly for the last month, with shares moving lower from its high of $10.62 to its recent low of $7 a share. During that downtrend, shares of AMRC have been consistently making lower highs and lower lows, which is bearish technical price action.

If you're in the bull camp on AMRC, then I would look for long-biased trades as long as this stock is trending above its recent low at $7 and then once it breaks out above some near-term overhead resistance levels at $7.75 to $8.17 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 156,382 shares. If that breakout hits soon, then AMRC will set up to re-test or possibly take out its next major overhead resistance levels at its 50-day of $8.88 a share to its 200-day at $9.29 a share.

Opko Health

One biopharmaceutical and diagnostics player that insiders are in love with here is Opko Health (OPK), which is engaged in the discovery, development and commercialization of novel and proprietary technologies. Insiders are buying this stock into notable strength, since shares are up around 13% so far in 2014.

Opko Health has a market cap of $3.9 billion and an enterprise value of $3.8 million. This stock trades at a premium valuation, with a price-to-sales of 40.64 and a price-to-book of 4.47. Its estimated growth rate for this year is -18.8%, and for next year it's pegged at 5.3%. This is not a cash-rich company, since the total cash position on its balance sheet is $185.80 million and its total debt is $227.74 million.

The CEO just bought 26,900 shares, or about $247,000 worth of stock, at $9.20 per share. The same CEO also just bought 28,000 shares, or about $264,000 worth of stock, at $9.45 per share.

From a technical perspective, OPK is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock is spiking modestly higher here right above both its 50-day and 200-day moving averages. This spike is starting to push shares of OPK within range of triggering a big breakout trade above some near-term overhead resistance levels.

If you're bullish on OPK, then I would look for long-biased trades as long as this stock is trending above some key near-term support levels at $9.03 or at $8.81 and then once it breaks out above some near-term overhead resistance levels $9.83 to $10.25 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 3.02 million shares. If that breakout triggers soon, then OPK will set up to re-test or possibly take out its next major overhead resistance levels at $11.65 to $12.95 a share.

Calamos Asset Management

One asset management player that insiders are active in here is Calamos Asset Management (CLMS), which provides investment advisory services to individuals, including high-net-worth individuals, and institutions. Insiders are buying this stock into major strength, since shares are up by 32% over the last six months.

Calamos Asset Management has a market cap of $260 million and an enterprise value of $-192 million. This stock trades at premium valuation, with a trailing price-to-earnings of 13 and a forward price-to-earnings of 20. Its estimated growth rate for this year is -39%, and for next year it's pegged at 10.7%. This is a cash-rich company, since the total cash position on its balance sheet is $545 million and its total debt is $92.11. This stock currently sports a dividend yield of 4%.

The CEO just bought 21,051 shares, or about $262,000 worth of stock, at $12.49 per share.

From a technical perspective, CLMS is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been trending sideways for the last month and change, with shares moving between $12.42 on the downside and $13.69 on the upside. Shares of CLMS are starting to bounce a bit higher of the lower-end of its range, which also sits right above its 50-day moving average at $12.18 a share.

If you're bullish on CLMS, then I would look for long-biased trades as long as this stock is trending above its 50-day at $12.18 and then once it breaks out above some near-term overhead resistance levels at $13.18 to $13.47 a share and then once it clears its 52-week high at $13.69 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 146,187 shares. If that breakout hits soon, then CLMS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $16 to $18 a share.

Aircastle

One final stock with some large insider buying is Aircastle (AYR), which acquires, leases and sells commercial jet aircraft to airlines worldwide. Insiders are buying this stock into notable strength, since shares are up 10% over the last six months.

Aircastle has a market cap of $1.5 billion and an enterprise value of $4.7 billion. This stock trades at a cheap valuation, with a trailing price-to-earnings of 47 and a forward price-to-earnings of 9.9. Its estimated growth rate for this year is 210%, and for next year it's pegged at 54%. This is not a cash-rich company, since the total cash position on its balance sheet is $654.61 million and its total debt is a whopping $3.88 billion. This stock currently sports a dividend yield of 4.2%.

A director just bought 30,000 shares, or about $561,000 worth of stock, at $18.70 per share.
From a technical perspective, AYR is currently trending below both tits 50-day and 200-day moving averages, which is bearish. This stock recently formed a double bottom chart pattern at $18.51 to $18.53 a share. Following that bottom, shares of AYR have started to spike higher and flirt with its 50-day moving average at $19.03 a share. That move is starting to push shares of AYR within range of triggering a near-term breakout trade.

If you're bullish on AYR, then look for long-biased trades as long as this stock is trending above those double bottom support levels and then once it breaks out above some near-term overhead resistance levels at $19.63 to $20.12 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 402,666 shares. If that breakout gets underway soon, then AYR will set up to re-test or possibly take out its 52-week high at $21.35 a share. Any high-volume move above that level will then give AYR a chance to tag $23 to $25 a share.

To see more stocks with notable insider buying, check out the Stocks With Big Insider Buying portfolio on Stockpickr.

-- Written by Roberto Pedone in Delafield, Wis.

RELATED LINKS:

Top 5 Small Cap Companies To Invest In Right Now

>>5 Rocket Stocks Ready for Blastoff

>>5 Toxic Stocks to Sell Now

>>5 Stocks Under $10 Set to Soar

Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Delafield, Wis., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including

CNBC.com and Forbes.com. You can follow Pedone on Twitter at www.twitter.com/zerosum24 or @zerosum24.

Apple, Boeing: R&D Cheapskates?

In 2013 the United States spent more corporate money on research and development than any other country in the world. Of a total spending level of €538.8 billion (about $738.3 billion), U.S.-based companies spent €189.1 billion, or 35.1% of the total. Japanese firms were the second-highest spenders, with 18.9% of the total, followed by Germany (10.5%), France (5.2%) and the United Kingdom (4.2%).

The data comes for the European Commission’s 2013 EU Industrial R&D Investment Scorecard and is based on information gathered on 2,000 companies from around the world.

Of the five companies spending the most, two are automakers, two are technology companies and one is technology conglomerate. The top spender was Volkswagen, followed by Samsung Electronics, Microsoft Corp. (NASDAQ: MSFT), Intel Corp. (NASDAQ: INTC) and Toyota Motor Corp. (NYSE: TM). Interestingly, the next five companies are all drug companies.

One company that spends relatively little is Apple Inc. (NASDAQ: AAPL). Apple spent about €$2.5 billion on R&D in 2013, according to the EU. In its annual report for its fiscal year ending in October, the company said it spent $4.5 billion on R&D.

R&D spending at Apple has ramped up seriously in the past few years. In fact Apple has spent nearly 50% of all its R&D spending since 1995 in the past three years. And as the money keeps rolling into Cupertino, the amount Apple spends on R&D as a percentage of net sales has fallen to 2.6% from a high of around 8% in 2001, the year the iPod was released.

One way to look at Apple’s R&D spending levels over the past decade or so is that the company has gotten a lot of bang out of relatively few bucks. But as iPod sales dwindle and smartphone and tablet markets either get saturated or move to countries where lower prices are the sales drivers, Apple may have to step up its spending on R&D.

Top 10 Logistics Stocks To Own For 2016

Another surprising omission from the EU’s list of the 50 biggest R&D spenders is Boeing Co. (NYSE: BA). EADS, the parent of arch-rival Airbus, spent more than €3.5 billion in 2013. The lowest spending level among the top 50 is about €2.4 billion. According to Boeing’s annual report for 2013, the company spent $3.1 billion on R&D last year, or about 3.5% of total revenue.

Top Media Stocks To Invest In Right Now

Top Media Stocks To Invest In Right Now: Cablevision Systems Corporation (CVC)

Cablevision Systems Corporation provides telecommunications and media services. It operates in two segments, Telecommunications Services and Other. The Telecommunications Services segment is involved in television business, including video, high-speed data, and VoIP operations, as well as the provision of commercial data and voice services. The Other segment offers Newsday, a daily newspaper; amNewYork, a free daily newspaper; and Star Community Publishing, a group of weekly shopper publications; and newsday.com and exploreLI.com. This segment also engages in motion picture theatre business, Clearview Cinemas; provision of the News 12 Networks, a regional news programming services; and the MSG Varsity network, a network covering high school sports and activities, and other local programs, as well as cable television advertising. Cablevision Systems Corporation was founded in 1985 and is headquartered in Bethpage, New York.

Advisors' Opinion:

• [By Will Ashworth]

  Losing control of the Cablevision (CVC) spinoff will ultimately be better for the Dolans than if they try to go it alone.

  This scenario's likely a long shot, but I think it makes a lot of sense.

• [By Anna Prior]

  Cablevision Systems Corp.(CVC) said it swung to a profit in the first quarter, driven by higher rates and advertising sales that boosted its cable revenue.

• [By WWW.DAILYFINANCE.COM]

  'Interconnection' The better access that Netflix is getting from Comcast is known as "interconnection," a term referring to digital content's journey to an Internet service provider's gates. That path technically isn't covered by the current definition of Net neutrality, which refers to how service providers treat digital content once it's inside the gates. Comcast has promised to honor the p! revious rules governing Net neutrality through 2018. In a blog post last month, Hastings argued that future Net neutrality guidelines should be expanded to address interconnection issues, too. "Without strong Net neutrality, big ISPs can demand potentially escalating fees for the interconnection required to deliver high quality service," Hastings wrote. "The big ISPs can make these demands -- driving up costs and prices for everyone else -- because of their market position." Google's YouTube video site and many other websites were paying interconnection fees to Comcast before Netflix struck its own deal with the carrier. Even with the March improvements, Comcast's delivery of Netflix content lags behind several other major service providers. Cablevision (CVC), Cox, Suddenlink and Charter (CHTR) each delivered Netflix video at higher speeds than Comcast in March, according to Monday's breakdown. Netflix has interconnection deals with Cablevision, Cox and Suddenlink, although those arrangements don't require Netflix to pay fees.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-media-stocks-to-invest-in-right-now.html

Hot Gas Stocks To Buy For 2016

Hot Gas Stocks To Buy For 2016: Western Gas Equity Partners LP (WGP)

Western Gas Equity Partners, LP, incorporated on September 11, 2007, was formed to own three types of partnership interests in Western Gas Partners, LP (WES). WES is a limited partnership formed by Anadarko Petroleum Corporation to own, operate, acquire and develop midstream energy assets. As of December 31, 2011, the Company had no independent operations. On January 13, 2012, WES acquired 100% interest of Mountain Gas Resources LLC (MGR). On August 1, 2012, WES acquired 24% interest of Chipeta Processing LLC (Chipeta).

WES is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, natural gas liquids (NGLs) and crude oil for Anadarko, as well as third-party producers and customers. The assets of WGP, through its partnership interests in WES, include thirteen gathering systems, seven natural gas treating facilities, ten natural gas processing facilities, two NGL pipelines, one interstate gas pipeline, one intrastate gas pipeline, and three separate interests in Fort Union, White Cliffs Pipeline, LLC (White Cliffs) and Rendezvous Gas Services, LLC (Rendezvous). These assets are located in East and West Texas, the Rocky Mountains (Colorado, Utah and Wyoming), and the Mid-Continent (Kansas and Oklahoma). WES also has facilities under construction in South Texas and northeast Colorado. During the year ended December 31, 2011, WES completed the construction of a cryogenic processing train at its Chipeta facility , which had a designed capacity of approximately 300 million cubic feet of natural gas per day and was placed into service in October 2012.

Advisors' Opinion:

• [By Jonas Elmerraji]

  The exact same setup is potentially giving traders a reason to jump into shares of $8.5 billion midstream gas company Western Gas Equity Partners (WGP). Just like Flotek, WGP is forming a textbook channel up. And this week, Western Gas is te! sting trendline support.

  It's a little too early to call WGP's trendline buyable here. At some point, all trends eventually fail -- and when this one does, you don't want to be left holding the bag. A bounce this week will be a good indication that WGP can still catch a bid at this price level. When and if that happens, I'd recommend keeping a tight protective stop in place just below WGP's most recent swing low at $38.

  While the 50-day moving average has been crossing paths with WGP quite a bit in the last month, I'd recommend ignoring it. The average hasn't acted as a meaningful support or resistance level to date. In the case of this particular name, it's just not technically relevant.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/hot-gas-stocks-to-buy-for-2016.html

10 Best Medical Stocks To Buy For 2015

For most of 2012 and 2013, Covidien (NYSE:COV) was the not-so-little med-tech that could. In an environment were companies like Johnson & Johnson (NYSE:JNJ), Bard (NYSE:BCR), Stryker (NYSE:SYK), and Abbott (NYSE:ABT) were struggling to deliver sustained attractive growth in devices, Coviden managed to do so. Now, though, it looks like the Street has caught up with Covidien's prospects and the sequential deceleration in device growth could make it harder for these shares to outperform. Still, as one of the best companies in a still-popular sector, I wouldn't be in a hurry to sell if I owned shares.

SEE: A Checklist For Successful Medical Technology Investment

Overall Performance Continues To Lead, But Slow Spots Are Appearing
With 3% reported growth and 4% organic growth, Covidien basically hit its mark for the fiscal third quarter. While revenue from the supplies business declined 1%, core device growth was up 6% on a constant currency basis, making it one of the strongest large-cap device growth names.

Top 5 Valued Stocks To Own Right Now: Prothena Corporation PLC (PRTA)

Prothena Corporation PLC, incorporated on September 26, 2012, is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion. Its pipeline includes NEOD001, PRX002 and PRX003. The Company�� work in protein misfolding could result in therapies to treat several neurodegenerative diseases, including AL (primary) and AA (secondary) forms of amyloidosis (NEOD001), Parkinson's disease and related synucleinopathies (PRX002). Its cell adhesion development activities could generate new therapies to treat inflammatory diseases and metastatic cancers (PRX003). The Company�� program, NEOD001, is in Phase 1. In addition to antibodies directed to neo-epitope targets, it is developing antibodies directed to other targets. The Company has generated antibodies against cell adhesion targets expressed on certain pathogenic Th17 immune cells and tumor cells.

The Company�� pipeline also includes several late discovery stage programs for which it is testing antibodies in preclinical models of disease. It is also generating additional antibodies against other targets involved in protein misfolding and cell adhesion for characterization in vivo and in vitro.

NEOD001 for Amyloidosis

NEOD001 is a monoclonal antibody that targets the amyloid that accumulates in both AL and AA forms of amyloidosis. The antibody was designed to not react with normal serum amyloid A and only with the aberrant cleaved form of the protein (amyloid A).

PRX002 for Parkinson�� Disease

The Company has generated antibodies targeting alpha-synuclein that may slow or reduce the neurodegeneration associated with synuclein misfolding and/or transmission. It has tested these antibodies in various cellular and animal models of synuclein-related disease. In a transgenic mouse model of Parkinson�� disease, passive immunization with 9E4, a murine ver! sion of PRX002, reduced the appearance of synuclein pathology, protected synapses and improved performance by the mice in behavioral testing. The humanized antibody product candidate PRX002 has advanced into manufacturing and preclinical testing.

PRX003 for Inflammatory Diseases and Cancers

The Company is developing PRX003, a monoclonal antibody targeting MCAM for the potential treatment of inflammatory diseases and cancers. It has generated monoclonal antibodies that block MCAM-mediated cell adhesion and have been shown to delay relapse and severity of relapse in a mouse model of multiple sclerosis known as experimental autoimmune encephalomyelitis. The Company�� antibodies are being tested in animal models of inflammatory diseases and cancers. Based on early results from these studies, it has identified a clinical candidate, PRX003. It has advanced this antibody into manufacturing and intends to advance this antibody into preclinical testing.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Equities Trading UP
  Prothena Corporation plc (NASDAQ: PRTA) shares shot up 21.60 percent to $45.19 after the company reported clinical data to be presented at International Symposium on Amyloidosis. Morgan Stanley raised the price target on the stock from $35.00 to $53.00.

• [By Lauren Pollock]

  Roche Holding AG(ROG.VX) has entered a pact with Prothena Corp.(PRTA) PLC to develop and commercialize a treatment the clinical-stage biotechnology firm is developing for Parkinson’s disease. In after-hours trading, Prothena’s stock rose 8.6% to $29.75 premarket.

10 Best Medical Stocks To Buy For 2015: Boston Scientific Corp (BSX)

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. During the year ended December 31, 2011, its products were offered for sale by seven core businesses: Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions, Urology/Women�� Health, Neuromodulation, and Electrophysiology. In January 2011, it completed the acquisition of Intelect Medical, Inc. In January 2011, it completed the acquisition of Sadra Medical, Inc. In March 2011, the Company completed the acquisition of Atritech, Inc. In February 2011, it announced the acquisitions of S.I. Therapies and ReVascular Therapeutics, Inc. In January 2011, the Company sold its Neurovascular business to Stryker Corporation. In June 2012, the Company acquired Cameron Health, Inc. of San Clemente, California and, as a result, added to its product portfolio subcutaneous implantable cardioverter defibrillator, called the S-ICD System.

Interventional Cardiology

The Company offers coronary stent product. Coronary stents are tiny, mesh tubes used in the treatment of coronary artery disease, which are implanted in patients to prop open arteries and facilitate blood flow to and from the heart. The Company offers a two-drug platform strategy with its paclitaxel-eluting and everolimus-eluting stent system offerings, and it offers a range of stent sizes. The Company markets its next-generation internally-developed and self-manufactured PROMUS Element stent system in the United States, its Europe/Middle East/Africa (EMEA) region and certain Inter-Continental countries, including China and India. It markets the PROMUS everolimus-eluting stent system, supplied to the Company by Abbott Laboratories, in Japan. It also markets its TAXUS paclitaxel-eluting stent line, including its third-generation TAXUS Element paclitaxel-eluting stent system in the U.nited States, Japan, EMEA and certain Inter-Continental countries.

The Compa! ny markets a line of products used to treat patients with atherosclerosis, a principal cause of coronary artery obstructive disease. Its product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA). The Company markets a family of intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels. The iLab Ultrasound Imaging System continues as its flagship console and is compatible with its line of imaging catheters. The system is designed to enhance the diagnosis and treatment of blocked vessels and heart disorders. Sadra is developing a repositionable and retrievable device for transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis. The Lotus Valve System consists of a stent-mounted tissue valve prosthesis and catheter delivery system for guidance and placement of the valve. Atritech has developed a device designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke. The WATCHMAN Left Atrial Appendage Closure Technology, developed by Atritech, is the first device proven in a randomized clinical trial to offer an alternative to anticoagulant drugs, and is approved for use in CE Mark countries.

Cardiac Rhythm Management

The Company develops, manufactures and markets a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including Implantable cardioverter defibrillator (ICD) systems used to detect and treat abnormally fast heart rhythms (tachycardia) that could result in sudden cardiac death, including implantable cardiac resynchronization therapy defibrillator (CRT-D) systems used to treat heart failure, and implantable pacemaker systems used to manage slow or irregular heart rhyth! ms (brady! cardia), including implantable cardiac resynchronization therapy pacemaker (CRT-P) systems used to treat heart failure. Its product offerings include its COGNIS cardiac resynchronization therapy defibrillator (CRT-D), its TELIGEN ICD systems and its ALTRUA family of pacemaker systems. During 2011, it began the United States launch of its next-generation line of defibrillators, INCEPTA, ENERGEN and PUNCTUA.

Endoscopy

The Company markets a range of products to diagnose, treat and ease a variety of digestive diseases, including those affecting the esophagus, stomach, liver, pancreas, duodenum, and colon. Common disease states include esophagitis, portal hypertension, peptic ulcers as well as esophageal, biliary, pancreatic and colonic cancer. The Company offers the Radial Jaw 4 Single-Use Biopsy Forceps, which are designed to enable collection of large high-quality tissue specimens without the need to use large channel therapeutic endoscopes. Its exclusive line of RX Biliary System devices are designed to provide greater access and control for physicians to diagnose and treat challenging conditions of the bile ducts, such as removing gallstones, opening obstructed bile ducts and obtaining biopsies in suspected tumors. The Company also markets the Spyglass Direct Visualization System for direct imaging of the pancreatico-biliary system. The Spyglass System is a single-operator cholangioscopy device that offers clinicians a direct visualization of the pancreatico-biliary system and includes supporting devices for tissue acquisition, stone management and lithotripsy. Its products also include the WallFlex family of stents, in particular, the WallFlex Biliary line and WallFlex Esophageal line; and in 2011, the Company launched its Advanix Biliary Plastic Stent System and the Expect Endoscopic Ultrasound Aspiration Needle in the United States and certain international markets. Its Resolution Clip Device is an endoscopic mechanical clip designed to treat gastrointestinal bleeding.

T! he Company markets devices to diagnose, treat and ease pulmonary disease systems within the airway and lungs. Its products are designed to help perform biopsies, retrieve foreign bodies from the airway, open narrowings of an airway, stop internal bleeding, and ease symptoms of some types of airway cancers. Its product line includes pulmonary biopsy forceps, transbronchial aspiration needles, cytology brushes and tracheobronchial stents used to dilate narrowed airway passages or for tumor management. Asthmatx, Inc. designs, manufactures and markets a less-invasive, catheter-based bronchial thermoplasty procedure for the treatment of severe persistent asthma. The Alair Bronchial Thermoplasty System, developed by Asthmatx, has both CE Mark and Food and Drug Administration (FDA) approval and is the first device-based asthma treatment approved by the FDA.

Peripheral Interventions

The Company sells various products designed to treat patients with peripheral disease, including a line of medical devices used in percutaneous transluminal angioplasty and peripheral vascular stenting. Its peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. In 2010 and 2011, it launched several of its products internationally, including the EPIC self-expanding nitinol stent system in certain international markets, and the Carotid WALLSTENT stent system in Japan. The Company launched three new peripheral angioplasty balloons in 2011, including its next-generation Mustang percutaneous transluminal angioplasty (PTA) balloon, its Coyote balloon catheter, a highly deliverable and ultra-low profile balloon dilatation catheter designed for a range of peripheral angioplasty procedures and its Charger PTA Balloon Catheter, a 0.035 inch percutaneous transluminal angioplasty balloon catheter designed for post-stent dilatation, as well as conventional balloon angioplasty to open blocked peripheral arteries. The Company has commenced a limited ma! rket rele! ase of its OFFROAD re-entry catheter system in certain international markets, and in February 2012, it launched its TRUEPATH intraluminal CTO device in the United States.

The Company sells products designed to treat patients with non-vascular disease. Its non-vascular suite of products include biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The Company continues to market its extensive line of Interventional Oncology product solutions, including the Renegade HI-FLO Fathom microcatheter and guidewire system and Interlock - 35 Fibered IDC Occlusion System for peripheral embolization. The Company�� FilterWire EZ Embolic Protection System is a filter designed to capture embolic material that may become dislodged during a procedure, which could otherwise travel into the microvasculature where it could cause a heart attack or stroke. It is commercially available in the United States, its EMEA region and certain Inter-Continental countries for multiple indications, including the treatment of disease in peripheral, coronary and carotid vessels. It is also available in the United States for the treatment of saphenous vein grafts and carotid artery stenting procedures.

Urology/Women�� Health

The Company�� Urology/Women�� Health division develops, manufactures and sells devices to treat various urological and gynecological disorders. The Company sells a variety of products designed to treat patients with urinary stone disease, stress urinary incontinence, pelvic organ prolapse and excessive uterine bleeding. The Company offers a line of stone management products, including ureteral stents, wires, lithotripsy devices, stone retrieval devices, sheaths, balloons and catheters.

The Company markets a range of devices for the treatment of conditions, such as female urinary incontinence, pelvic floor reconstruction (rebuilding of the anatomy to its original state), and ! menorrhag! ia (excessive menstrual bleeding). It offers a breadth of mid-urethral sling products, sling materials, graft materials, pelvic floor reconstruction kits, and suturing devices. The Company markets its Genesys Hydro ThermAblator (HTA) system, a next-generation endometrial ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia. The Genesys HTA System features a smaller and lighter console, simplified set-up requirements, and an enhanced graphic user interface and is designed to improve operating performance.

Neuromodulation

The Company within its Neuromodulation business markets the Precision Spinal Cord Stimulation (SCS) system, used for the management of chronic pain. In 2011, the Company launched its Clik Anchor for its Precision Plus SCS System, a rechargeable SCS device for chronic pain management. During 2011, it received FDA approval for and launched the Infinion 16 Percutaneous Lead, a 16-contact percutaneous lead. The Company also markets the Linear 3-4 and Linear 3-6 Percutaneous Leads for use with its SCS systems, which are designed to provide physicians more treatment options for their chronic pain patients. Intelect Medical, Inc. is a development-stage company developing advanced visualization and programming for the Vercise system.

Electrophysiology

The Company within its Electrophysiology business develops less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart. Included in its product offerings are radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Its products include the Blazer and Blazer Prime line of temperature ablation catheters, designed to deliver enhanced performance, responsiveness, and durability. Its cooled ablation portfolio includes the closed-loop irrigated catheter on the market, the Chilli II cooled! ablation! catheter, and the newly launched Blazer Open-Irrigated ablation catheter with a Total Tip Cooling Design.

The Company competes with Abbott Laboratories, Medtronic, Inc., St. Jude Medical, Inc. and Johnson & Johnson.

Advisors' Opinion:

• [By Brian Orelli]

  Dragging down sales were medical devices, which saw sales drop 3% at constant currency. Much of the decline came from sales of its drug-eluting stent and related products, which fell 15% in the U.S. compared to the first quarter of 2012. U.S. sales are being dragged down by pricing pressure as it competes with Boston Scientific (NYSE: BSX  ) and decreased usage by the doctors. Boston Scientific reported a similar experience with U.S. sales of drug-eluting stents down a whopping 33%.

• [By Ben Levisohn]

  The S&P 500 gained 0.3% to 1,843.80 today as Boston Scientific (BSX), Dow Chemical (DOW) and Biogen Idec (BIIB) rose. The Dow Jones Industrial Average slid 0.3% to 16,414.44.

10 Best Medical Stocks To Buy For 2015: Koninklijke Philips NV (PHIA)

Koninklijke Philips NV, formerly Koninklijke Philips Electronics NV, is the Netherlands-based parent company of the Philips Group (Philips). The Company operates within three main business sectors, such as Healthcare, Consumer Lifestyle, and Lighting, as well as through the Innovation, Group & Services (IG&S) sector. The Healthcare sector offers both personal care and professional products, such as computer tomography equipment, radiography equipment and refurbished systems. Consumer Lifestyle sector offers a range of sound, vision, personal devices and household products, such as television, headphones, kitchen appliances, shavers and digital cameras, among others. Lighting sector offers lighting products, such as professional lamps, light-emitting diodes (LED), ballasts and luminaires, among others. The IG&S segment provides the operating sectors with support through shared service centers. It also includes projects which are not part of the operating sectors. Advisors' Opinion:

• [By Corinne Gretler]

  European stocks rose for a fourth day, extending a seven-week high, as companies from UBS AG to Royal Philips (PHIA) Electronics NV reported increased profit.

10 Best Medical Stocks To Buy For 2015: OncoSec Medical Inc (ONCS)

OncoSec Medical Incorporated, incorporated on February 8, 2008, is an emerging drug-medical device company. The Company focused on designing, developing and commercializing medical approaches for the treatment of solid cancers. In March 2011, the Company acquired from Inovio Pharmaceuticals, Inc. (Inovio) certain assets related to the use of drug-medical device combination products for the treatment of different cancers.

The Company�� acquired assets relate to certain non-deoxyribonucleic acid (DNA) vaccine technology and property relating to selective tumor ablation technologies, which it refers to as the OncoSec Medical System (OMS), a therapy which uses an electroporation device to facilitate delivery of chemotherapy agents, or nucleic acids encoding cytokines, into tumors and/or surrounding tissue for the treatment and diagnosis of various cancers. As of January 24, 2012, the Company had not generated any revenue from operations.

Advisors' Opinion:

• [By James E. Brumley]

  How does the old saying go? Beggars can't be choosers? Two weeks ago, yours truly penned some bullish comments regarding OncoSec Medical Inc. (OTCMKTS:ONCS). The long and short of it was, if ONCS could clear a technical ceiling around $0.36, then life would get much easier for the bulls.

• [By James E. Brumley]

  If you're looking for the next big biotech breakout stock, then OncoSec Medical Inc. (OTCMKTS:ONCS) deserves a place on your watchlist. This volatile cancer play has been down more than up 2011, but if you look closely at a long-term chart of ONCS, you may find it's already wiggled its way into a new uptrend. And, it may be only a matter of time before the bullish fireworks start to go off.

• [By John Udovich]

  Small cap biotech stocks AVEO Pharmaceuticals, Inc (NASDAQ: AVEO), OncoSec Medical Inc (OTCMKTS: ONCS) and MetaStat Inc (OTCBB: MTST) are focused on or are developing treatments or diagnostic technologies for metastatic cancers. In case you aren�� familiar with the term metastasis or metastatic, it�� the�spread of cancer from its primary site to other places in the body as cancer cells break away from a primary tumor, penetrate into lymphatic and blood vessels, circulate through the bloodstream and then grow in a new focus (metastasize) in normal tissues elsewhere in the body. In other words, it�� a dangerous form of cancer, but there are some small cap biotech stocks targeting it for diagnostics or treatment:

10 Best Medical Stocks To Buy For 2015: Digirad Corp (DRAD)

Digirad Corporation, incorporated in 1997, is the developer and manufacturer of medical diagnostic imaging systems, including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications. The Company operates in two segments: DIS (its diagnostic imaging service business) and its product segment. Through DIS, the Company provides in-office imaging services to physicians, offering certified personnel, required licensure, an imaging system and other support and supplies for the performance of nuclear and ultrasound imaging procedures under the supervision of its physician customers. The Companies imaging systems are sold in both portable and fixed configurations. DIS physician customers enter into annual lease contracts for imaging services generally delivered on a per-day basis. The Company�� product segment sells solid-state gamma cameras and provides camera service and maintenance.

Imaging Services

DIS offers portable nuclear and ultrasound imaging services. Its nuclear modality services include an imaging system, a certified nuclear medicine technologist and a cardiac stress technician, often certified or a trained nurse or paramedic, the supply of radiopharmaceuticals, and required licensing services for the performance of nuclear imaging procedures under the supervision of physicians. The ultrasound imaging service is similar, in that the Company provides the ultrasound equipment and one ultrasound technologist. Its portable nuclear imaging operations use a hub and spoke model, in which centrally located regional hubs anchor multiple van routes in the surrounding metropolitan areas. At its DIS hubs, clinical personnel load the equipment, radiopharmaceuticals, and other supplies onto specially equipped vans for transport to the physician�� office or other customer locations, where they set up the equipment for the day. The Company provides nuclear and ultrasound services primarily under annual contracts for services delivered on a per-day ! basis.

Products

Digirad markets and manufactures a line of nuclear medicine cameras for nuclear cardiology and general nuclear medicine applications. Its cameras are used in hospitals, imaging centers, physician offices and by mobile service providers. Its nuclear cameras feature detectors based on solid-state technology developed by the Company. The solid-state technology provides the Company with the capability to market and manufacture a diverse family of cardiac and general-purpose cameras.

The Cardius family of cardiac SPECT (single-photon emission computerized tomography) solid-state imagers makes it possible to image patients up to 500 pounds in a sitting position. Upright imaging makes it possible to image bariatric, COPD (chronic obstructive pulmonary disease) or claustrophobic patients that typically could not be imaged lying down on. The Company offers fixed dual-head and triple-head cardiac camera models for use within a facility and a portable dual-head configuration that makes it possible to move the system to provide service to multiple rooms or sites. Its flagship in cardiology is the Cardius XACT SPECT/CT system. It features a triple-head design and a low dose volume computed tomography (CT) attenuation correction methodology.

The Company�� ergo is a large-field-of-view planar portable imaging camera. The ergo imaging system is targeted to hospitals with multi-camera general nuclear medicine departments, academic centers, pediatric hospitals, regional trauma centers, women�� health centers and cancer centers. The Company also provides triple-head Cardius 3 XPO system, which provides shorter image acquisition time. Its Cardius X-ACT camera is a rapid cardiac SPECT/VCT imager. The Cardius X-ACT camera is positioned more toward the hospital and larger cardiology practices.

Advisors' Opinion:

• [By John Kell and Tess Stynes var popups = dojo.query(".socialByline .popC"); p]

  Digirad Corp.(DRAD) agreed to pay at least $3.5 million in cash to acquire medical-outsourcing provider Telerhythmics, a deal that will add to the larger company’s sales and bottom line.

• [By Lisa Levin]

  Digirad (NASDAQ: DRAD) shares created a new 52-week high of $3.989 on Q3 results.

  Posted-In: 52-Week HighsNews Intraday Update Markets Movers

10 Best Medical Stocks To Buy For 2015: Alere Inc (ALR)

Alere Inc., incorporated on May 11, 2001, is a provider of point-of-care diagnostics and services. The Company's products and services help healthcare practitioners make treatment decisions and improve outcomes for individuals living with chronic disease. The Company's portfolio also includes a range of health information solutions that access to critical health data, provide clinical decision support, and facilitate performance reporting and analysis. The Company�� segment includes professional diagnostics, health information solutions and consumer diagnostics. The Company distributes its professional diagnostic products to hospitals, reference laboratories, physician offices and other point-of-care settings through an worldwide distribution networks. In February 2013, the Company acquired Epocal, Inc.

Professional Diagnostics

Professional diagnostics are generally designed to assist medical professionals in both preventative and interventional medicine, and include testing and monitoring performed in hospitals, laboratories and doctors' offices and, increasingly, patient self-testing, which the Company defines as testing or monitoring performed at home under the supervision of a medical professional. Professional diagnostic products provide for qualitative or quantitative analysis of patient samples for evidence of a specific medical condition, disease state or toxicological state or to measure response to therapy. The point-of-care market for rapid diagnostic products includes all areas where a patient is assessed or diagnosed, including hospitals, laboratories, physician offices, specialized mobile clinics, emergency rooms, rapid-response laboratories and patient health screening locations.

The Company's Alere Cholestech LDX System is a point-of-care monitor of blood cholesterol and related lipids which is used to test patients at risk of, or suffering from, heart disease and related conditions. The Alere Cholestech LDX System makes it possible to provide ! a complete lipid profile with tests for total cholesterol, high-density lipoprotein cholesterol (HDL) and low-density lipoprotein cholesterol (LDL), triglycerides, and glucose. The Company's Alere INRatio System is an easy-to-use, hand-held blood coagulation monitoring system for use by patients and healthcare professionals in the management of warfarin, a commonly prescribed medication used to prevent blood clots. The Company also offers the epoc Blood Analysis System for bloods gas, electrolyte and metabolite testing, which is manufactured by its recently acquired Epocal division. The epoc (enterprise point-of-care) platform is a point-of-care analysis system which provides Wireless bedside blood gas, electrolyte and metabolite measurement testing solutions and complements the Company's Alere Triage products in cardiology and emergency room settings.

The Company develops and markets a range of point-of-care tests for influenza A/B, RSV, strep throat, pneumonia, C. difficile, infectious mononucleosis, HIV, herpes simplex virus (HSV-2), hepatitis C (HCV), hepatitis B (HBV), malaria, lyme disease, Chlamydia, H. pylori, rubella and other infectious diseases. The Company's tests for infectious disease are sold under brand names that include Alere, Alere Determine, Acceava, BinaxNOW, Clearview, DoubleCheckGold, Panbio, SD, TECHLAB and Alere TestPack. In addition to point-of-care products, the Company also offers a line of indirect fluorescent antibody, or IFA, assays for over 20 viral, bacterial and autoimmune diseases, a full line of serology diagnostic products covering a range of disease categories and over 50 enzyme-linked immunosorbent assay (ELISA), tests for a range of infectious and autoimmune diseases, as well as a full line of automated instrumentation for processing ELISA tests.

The Company offers laboratory-based testing services throughout Europe under the name Alere Toxicology, formerly Concateno, and in the United States under the names Alere Toxicology Services, or! Alere To! xicology, and Redwood Toxicology Laboratory, or Redwood. The Company offers point-of-care diabetes products, including its Afinion Analyzer System and its NycoCard System. The Company's Alere Connect products include HealthPAL and HealthCOM.

Health Information Solutions

The Company's health information solutions are designed to provide physicians with actionable data that allows them to make more decisions in real time, deliver quality care, and put the individuals they treat on a pathway to better health. The Company offers a range of software-based analytics, clinical decision support tools, and accountable cares programs that enable healthcare providers to initiate earlier interventions, personalize treatment plans, lower costs by reducing hospital readmissions, and measure improvements in outcomes at both a patient and population level. With this range of scalable solutions, the Company is able to support healthcare practitioners in the transition to accountable care, as well as in meeting the new pay-for-performance guidelines set by the Centers for Medicare & Medicaid Services (CMS).

The Company's Women's and Children's Health division delivers a range of obstetrical care services that range from risk assessments focused on identifying women who may experience pregnancy complications to a neonatal program that supports early infant care management. The Company offers home-based obstetrical monitoring for pregnant women with medical or pregnancy-related problems that could puts their health or the health of their babies at risk. The Company also delivers telephonic and home-based nursing services that support improved clinical outcomes. The Company offers a suite of integrated wellness programs and resources that is designed to reduce participant health risks and healthcare-related costs. The Company's wellness programs include screening for risk factors associated with chronic disease, particularly tobacco use, poor nutrition, physical inactivity, and chron! ic stress! .

The Company offers services designed to support anticoagulation management for patients who takes warfarin to control their risk for stroke and clotting disorders. Alere Home Monitoring, the Company's patient self-testing business, assists patients in acquiring home INR monitors and with insurance coverage determinations and provides physicians with a comprehensive model that allows them to incorporate patient self-testing into their practices.

Consumer Diagnostics

The Company's consumer diagnostic products consist of the Company's First Check brand of over-the-counter drug tests for at-home testing for up to seven illicit drugs and five prescription drugs, as well as First Check brand over-the-counter tests for cholesterol monitoring. The Company also sells Balance Activ Vaginal Gel directly to consumers and healthcare professionals for the treatment of bacterial vaginosis without antibiotics.

The Company competes with Abbott, Siemens, Beckman Coulter, Johnson & Johnson, Roche, Abaxis Medical Diagnostics, International Technidyne Corporation, INOVA Diagnostics, DiaSorin, Diamedx and Qiagen.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Alere (NYSE: ALR  ) , whose recent revenue and earnings are plotted below.

10 Best Medical Stocks To Buy For 2015: KaloBios Pharmaceuticals Inc (KBIO)

KaloBios Pharmaceuticals, Inc., is a United States-based company, which develops protein therapeutics. The Company develops and engineers antibodies and protein therapeutics. Its monoclonal antibodies (mAbs) technology that is being used for reengineering antibodies with products being developed in the areas of infectious disease, autoimmunity, and oncology. Its suite of technologies can also be used for discovery and engineering of other proteins, industrial enzymes and small molecule drugs. It conducts three clinical development programs in leukemia, infectious diseases, and autoimmune diseases. Advisors' Opinion:

• [By Monica Gerson]

  KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO) shares fell 64.48% to $0.65 in pre-market trading after the company reported top-line data from phase 2 study of KB001-A.

Hot New Companies To Buy Right Now

Hot New Companies To Buy Right Now: Green Technology Solutions Inc (GTSO)

Green Technology Solutions Inc (GTSO), incorporated on February 22, 1991, is in the business of identifying and acquiring rights in early stage, green technologies, with the plan to develop these technologies into marketable products. The Company has identified several technology endeavors.

As of December 31, 2011, the Company has identified the advancement of mining technologies, with an emphasis on rare earth and precious metals mining applications, the development of additional markets for existing paint products that are being marketed in the United States, and smart grid technology. GTSO has also identified additional joint venture in China and South America.

Advisors' Opinion:

• [By CRWE]

  Today, GTSO surged (+10.29%) up +0.0035 at $.0375 with55,329 shares in play thus far (ref. google finance Delayed: 12:20PM EDT August 27, 2013).

  Green Technology Solutions, Inc. is negotiating a potentially lucrative spot transaction with joint venture partner Chilerecicla to export a large quantity of e-waste to one of the largest smelters in the world.

  According to the terms of the spot transaction, GTSO joint venture partner Chilerecicla will collect several metric tons of e-waste from suppliers based in Bolivia and Chile, and then ship materials to a smelter overseas. The buyers consist of the worlds largest smelter, who has meticulously screened Chilerecicla to become one of its suppliers. The smelter has noted that its capacity to purchase e-waste from Chilerecicla exceeds our partners current e-waste forecast for the near and present future

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/hot-new-companies-to-buy-right-now-2.html

Hot Low Price Stocks To Buy Right Now

When markets reach highs and beat records, investing conversations start to talk about the "dumb money." The�dumb money�is not my term, by the way; it's how Wall Street refers to individual investors who repeatedly sell stocks at a low price, only to turn around later and buy them for high prices.

If the mistake is so frequent that it actually has a name, why do we keep doing it, and what can we do to stop?

When we make financial decisions we're faced with a choice: Do we act based on what we know or how we feel?

In an intellectual exercise, knowledge wins. But in the real world, we're hardwired to pursue the things that give us pleasure or provide security and run as fast as possible from the things that cause us pain. This genetic trait means that we're often driven by how we feel instead of what we know.

Here is an example. In December 2008, The Economist published one of its classic covers. I remember seeing this cover, and a year or so later being struck by how well the image captured how I had felt. In fact, when I saw it again I had an emotional response that surprised me as I thought back to those feelings. The picture made me feel like everyone else did during that time. I was depressed, sad, hopeless, and felt like I was a fool for not gathering what little gold I had left before it too fell into the dark, bottomless hole pictured on the cover.

Top 10 Low Price Companies To Watch In Right Now: Alliance Data Systems Corporation (ADS)

Alliance Data Systems Corporation, together with its subsidiaries, provides data-driven and transaction-based marketing, and customer loyalty solutions primarily in the United States and Canada. The company operates in three segments: LoyaltyOne, Epsilon, and Private Label Services and Credit. The LoyaltyOne segment includes AIR MILES Reward Program that enables consumers to earn AIR MILES reward miles as they shop within a range of retailers and other sponsors participating in the AIR MILES Reward Program; and offers loyalty services, including loyalty consulting, customer analytics, and creative services. The Epsilon segment provides integrated direct marketing solutions, which combine database marketing technology and analytics with a range of direct marketing services comprising email marketing campaigns. This segment's products and services consist of marketing database services, analytical services, strategic consulting and creative services, proprietary data service s, and digital communications. The Private Label Services and Credit segment encompasses credit card processing, billing and payment processing, customer care and collections services for private label retailers, as well as private label retail credit card receivables financing, including securitization of the credit card receivables that it underwrites from its private label retail credit card programs. The company serves financial services, specialty retail, grocery and drugstore chains, petroleum retail, technology, hospitality and travel, media, and pharmaceuticals end markets. Alliance Data Systems Corporation was founded in 1996 and is headquartered in Plano, Texas.

Advisors' Opinion:

• [By Lee Jackson]

  Alliance Data Systems Corp. (NYSE: ADS) has had a very strong year so far. The company and its combined businesses are North America’s largest and most comprehensive provider of transaction-based, data-driven marketing and loyalty solutions serving large, consumer-based industries. The Thomson/First Call price target for the stock is set at $220.

• [By Monica Gerson]

  Breaking news

  Whirlpool (NYSE: WHR) reported a strong rise in its third-quarter earnings. For the year, Whirlpool lifted its earnings forecast to $9.90 to $10.10 per share, versus its July outlook of $9.50 to $10 per share. To read the full news, click here. Questcor Pharmaceuticals (NASDAQ: QCOR) announced today that it will commence a Phase 2 study to explore the efficacy and safety of H.P. Acthar庐 Gel (repository corticotropin injection) for Acute Respiratory Distress Syndrome (ARDS). To read the full news, click here. Centene (NYSE: CNC) reported a stronger-than-expected third-quarter profit. Centene's quarterly net earnings surged to $49.4 million, or $0.87 per share, up from $3.8 million, or $0.07 per share, in the year-ago period. To read the full news, click here. Dwolla and Alliance Data Systems (NYSE: ADS) today announced they have signed a new, multi-year agreement for Alliance Data's Retail Services business to provide a cardless private label credit product for the Dwolla payment network. To read the full news, click here.

  Posted-In: Morgan Stanley US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

• [By Garrett Cook]

  Toward the end of trading Friday, the Dow traded down 0.60 percent to 16,947.43 while the NASDAQ declined 0.75 percent to 4,557.59. The S&P also fell, dropping 0.83 percent to 1,980.97.

  Leading and Lagging Sectors Cyclical consumer goods & services shares fell by just 0.50 percent in trading on Friday. Top gainers in the sector included ULTA Salon, Cosmetics & Fragrance NASDAQ: (ULTA), up 17.5 percent, and 1-800-Flowers.com (NASDAQ: FLWS), up 4.5 percent. In trading on Friday, utilities shares were relative laggards, down on the day by about 1.89 percent. Meanwhile, top decliners in the sector included Companhia Energética de Minas Gerais - CEMIG (NYSE: CIG), down 4.7 percent, and CPFL Energia SA (NYSE: CPL), off 4.3 percent. Top Headline Darden Restaurants (NYSE: DRI) reported better-than-expected fiscal first quarter earnings. The Orlando, Florida-based company reported a quarterly loss of $19.3 million, or $0.14 per share, versus a year-ago profit of $42.2 million, or $0.32 per share. Excluding non-recurring items, the company earned $0.32 per share. Its sales surged to $1.6 billion versus $1.53 billion. However, analysts were expecting earnings of $0.30 per share on revenue of $1.6 billion. Equities Trading UP Conversant (NASDAQ: CNVR) shares shot up 30.25 percent to $34.79 after Alliance Data Systems (NYSE: ADS) announced its plans to buy Conversant for $35 per share. Shares of ULTA Salon, Cosmetics & Fragrance (NASDAQ: ULTA) got a boost, shooting up 17.69 percent to $114.72 after the company reported upbeat second-quarter results and raised its outlook. The company also unveiled a five-year plan for impressive growth. Sportsman's Warehouse Holdings (NASDAQ: SPWH) shares were also up, gaining 15.89 percent to $7.00 after the company reported stronger-than-expected fiscal second-quarter results. Equities Trading DOWN Shares of Ruckus Wireless (NASDAQ: RKUS) were down 5.19 percent to $14.35. Buckingham
• [By Dan Caplinger]

  Facebook certainly took the spotlight in the decision from S&P Dow Jones Indices to include the social media giant in the S&P 500. But lost in the Facebook news was the fact that Alliance Data Systems (NYSE: ADS  ) and Mohawk Industries (NYSE: MHK  ) also gained admission to the prestigious index, while Abercrombie & Fitch (NYSE: ANF  ) , JDS Uniphase (NASDAQ: JDSU  ) , and Teradyne (NYSE: TER  ) made their exit. Let's take a closer look at the other winners and losers in the Facebook index shuffle.

Hot Low Price Stocks To Buy Right Now: Eaton Vance Tax-Managed Global Diversified Equity Income Fund (EXG)

Eaton Vance Tax-Managed Global Diversified Equity Income Fund (the Fund) is a diversified, closed-end investment company. The Fund was established to offer investors sources of potential tax-advantaged income and gains. The Fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The Fund pursues its investment objectives by investing primarily in a diversified portfolio of domestic and foreign common stocks. The Fund invests primarily in dividend-paying domestic and foreign common stocks that qualify for favorable federal income tax treatment. In addition, the Fund writes (sells) stock index call options with respect to a portion of its common stock portfolio value. As of October 31, 2007, the Fund had written call options on 49.9% of its equity holdings. The Fund�� 10 largest equity holdings as of October 31, 2007, included Enel SPA, Nokia Oyj ADR, ENI SPA, Royal Dutch Shell PLC, BP PLC, Cesky Telecom AS, GlaxoSmithKline PLC, EMC Corp., HSBC Holdings PLC and Anadarko Petroleum Corp.

The Fund may invest in Cash Management Portfolio (Cash Management), an affiliated investment company managed by Boston Management and Research (BMR), a subsidiary of Eaton Vance Management (EVM). The Fund had a total return of -4.64% for the period from inception on February 27, 2007, to October 31, 2007.

Advisors' Opinion:

• [By Vivian Lewis]

  Eaton Vance Tax-Managed Global Equity Income Fund (EXG) favors active management in a declining market based on CIO Michael Wilson's strategy for closed end funds.

Hot Low Price Stocks To Buy Right Now: BNP Paribas SA (BNP)

BNP Paribas SA is a France-based bank group with four core businesses: Retail Banking, Corporate & Investment Banking, Investment Solutions and Other Activities. Retail Banking comprises the French retail banking division, Banca Nazionale del Lavoro in Italy, BeLux Retail Banking, Europe-Mediterranean, all BNP Paribas Group retail banking businesses out of Euro Zone: in the United States, in Asia, in the Mediterranean Basin and Africa, in Turkey, Central and Eastern Europe, personal finance and equipment solutions. The Corporate & Investment Banking business provides to its clients financing, advisory and capital markets services. The Investment Solutions division offers private banking, asset management, securities services, real estate and insurance services. In November 2013, the Company launched 'Hello Bank!', a mobile, digital bank operating in France, Belgium and Germany. Advisors' Opinion:

• [By Namitha Jagadeesh]

  BNP Paribas SA (BNP), Societe Generale SA (GLE) and Credit Agricole SA (ACA), France�� largest banks by market value, reported second-quarter profit that exceeded analysts��estimates. Paris-based Societe Generale, which said income more than doubled from a year earlier, trades at 10.8 times projected earnings, 64 percent below its 2009 high. Credit Agricole trades at 8.6 times projected profit and BNP Paribas at 10.7 times, according to data compiled by Bloomberg.

Hot Low Price Stocks To Buy Right Now: Fujitsu Ltd (FJTSY)

Fujitsu Limited (Fujitsu), incorporated on June 20, 1935, is engaged in providing solutions in the field of information and communication technology. Along with multifaceted services provision, its business consists of the development, manufacture, sales and maintenance of the high-quality products and electronic devices that make these services possible. The Company operates in three segments: technology solutions, ubiquitous products solutions and device solutions. On June 4, 2009, Fujitsu introduced the docomo PRIME series F-09A mobile handset. On July 15, 2009, Fujitsu announces acquisition of shares in information technology (IT) subsidiary of AUTOBACS SEVEN. In October 2010, the Company and Toshiba Corporation announced that they have completed the merger of their mobile phone businesses. Effective August 15, 2013, Intel Corp acquired Fujitsu Semiconductor Wireless Products Inc, from Fujitsu Semiconductor Ltd, a wholly owned subsidiary of Fujitsu Ltd.

Technology solutions

Fujitsu provides solutions/system integration services focused on information system consulting and integration, and infrastructure services centered on outsourcing services (complete information system operation and management). Fujitsu offers system products, such as servers and storage systems, which form the backbone of information systems, along with network products, such as mobile phone base stations, optical transmission systems and other communications infrastructures. Its services include system integration (system construction), consulting, front-end technologies (automated teller machines (ATMs)), outsourcing services (datacenters, IT operation/management, software as a service (SaaS), application operation/management and business process outsourcing), network services (business networks, distribution of Internet/mobile content), system support services (maintenance and surveillance services for information systems and networks) and security solutions (installation of information systems an! d networks).

Ubiquitous products solutions

Fujitsu offers the personal computers (PCs), mobile phones and other products indispensable for realizing the emerging ubiquitous networked society. In PCs, along with more conventional desktop and notebook models, the Company develops netbooks and products with security features, providing a global lineup that allows customers to choose the product for their application. In mobile phones, it provide a variety of products that include high-performance models featuring specs and water resistance, separable mobile phone handset, and products created from collaborations with brands. Its products include PCs, mobile phones and optical transceiver modules.

Device solutions

LSI devices and electronic components comprise Fujitsu�� Device Solutions. Fujitsu Semiconductor, the Fujitsu operating company in semiconductors, provides LSI devices found in products, such as digital home appliances, automobiles, mobile phones and servers. The Company�� subsidiaries Shinko Electric Industries Co., Ltd. and Fujitsu Component Limited, along with FDK Corporation, provide semiconductor packages and other electronic components, as well as structural components, such as batteries, relays and connectors. Its products include LSI devices, electronic components (semiconductor packages), batteries and structural components (relays and connectors).

Advisors' Opinion:

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- A rising Japanese yen and weak results from Caterpillar Inc. (CAT) overnight sent Tokyo-listed shares lower in early Thursday trade, with the Nikkei Stock Average (JP:NIK) falling 0.4% to 14,363.59, while the Topix also lost 0.4%. With the U.S. dollar remaining below the 98-yen level amid concerns about the health of China's largest banks, some currency-sensitive shares extended their losses after driving the Nikkei Average down 2% in the previous session. Among them, trading house Mitsui & Co. (JP:8031) (MITSY) fell 1.3%, retail major J. Front Retailing Co. (JP:3086) lost 1.2%, auto maker Nissan Motor Co. (JP:7201) (NSANY) retreated 0.6%, and Fujitsu Ltd. (JP:6702) (FJTSY) traded 1% lower. The below-forecast quarterly results and outlook cut from U.S. construction-equipment maker Caterpillar sent its Japanese rivals tumbling, with Komatsu Ltd. (JP:6301) (KMTUF) dropping 3.5% and Hitachi Construction Macheriny Co. (JP:6305) (HTCMF) falling 3.1%. On the upside, Hitachi Ltd. (JP:6501) (HTHIF) soared 5.4% after raising its profit and revenue guidance for the fiscal first hal

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- Japanese stocks weakened in early Thursday trading as the yen rose and Wall Street ended mixed, with the Nikkei Stock Average (JP:NIK) falling 1.2% to 15,929.74 after a 1.9% advance a day earlier. With the yen (USDJPY) slightly firmer than in the previous session, some investors sold currency-sensitive exporters, with Fanuc Corp. (JP:6954) (FANUF) down 2%, Kyocera Corp. (JP:6971) (KYOCF) off 1.9%, and Fujitsu Ltd. (JP:6702) (FJTSY) losing 2.3%. News that China would lift a ban on some sales of videogame consoles had sent shares of Nintendo Co. (JP:7974) (NTDOF) shooting 11% higher on Wednesday, but apparent profit-taking sent the stock down 4.2% in early Thursday action. Shares of rival Sony Corp. (JP:6758) (SNE) , however, followed with a 4% rise, also possibly buoyed by a Nikkei Asian Review report that it was planning a "smartphone offensive" in the U.S. and China. Canon Inc. (JP:7751) (CAJ) fell 2% on a separate Nikkei report that the company's 2013 operating profit would miss forecasts. Toshiba Corp. (JP:6502) (TOSYY)

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- Japanese stocks rose in early Monday trading, with weaker-than-expected trade data pushing the yen lower, which in turn helped some export stocks. The Nikkei Stock Average (JP:NIK) added 1% to 14,704.36, with the broader Topix up 0.8%, also enjoying support from gains Friday in the U.S. After data showing exports grew less than analysts had projected, the dollar (USDJPY) moved back above the 98-yen level, sending some exporters climbing, with a 2.2% rise for Fujitsu Ltd. (JP:6702) (FJTSY) , a 1.2% improvement for Alps Electric Co. (JP:6770) , and a 1% bump for Toyota Motor Corp. (JP:7203) (TM) . Shares of Suzuki Motor Corp. (JP:7269) (SZKMF) added 2.9% after a Nikkei report saying the company would record its highest-ever operating profit for the April-September half. Retailers were also a strong spot Monday, with J. Front Retailing Co. (JP:3086) up 2%, online marketplace Rakuten Inc. (JP:4755) (RKUNF) adding 2.4%, and 7-Eleven operator Seven & I Holdings Co. (JP:3382) (SVNDF) ahead by 1.4%.

Hot Low Price Stocks To Buy Right Now: Symmetry Medical Inc (SMA)

Symmetry Medical Inc. designs, develops, and produces implants and related surgical instruments and cases to orthopedic device manufacturers worldwide. It offers orthopedic implants that are used in reconstructive surgeries to replace or repair hips, knees, and other joints, such as shoulders, ankles, and elbows; trauma implant systems, which are used primarily to reattach or stabilize damaged bone or tissue while the body heals; and spinal implant systems, including plates and screws used by orthopedic surgeons and neurosurgeons in the treatment of degenerative diseases, deformities, and injuries in various regions of the spine. The company also provides surgical instruments, such as knee cutting blocks, osteotome revision systems, reamers, and retractors used in hip, knee, and shoulder reconstruction procedures, as well as in spinal, trauma, and other implant procedures. In addition, it produces a range of plastic, metal, and hybrid orthopedic cases to store, transport, and arrange surgical instruments and related implant systems, and other medical devices for orthopedic device manufacturers; endoscopy cases for endoscope sterilization; dental cases used in dental implant and general dental procedures; sterilization containers for the sterilization of various surgical instruments; and other cases for arthroscopy, osteobiologic, cardiovascular, ophthalmology, and diagnostic imaging, as well as ear, nose, and throat procedures. Further, the company engages in the design, engineering, and manufacturing of aerospace products comprising net shaped aerofoils and non-rotating aircraft engine forgings produced for the aerospace customers; and offers aerospace machining capabilities. The company was founded in 1976 and is headquartered in Warsaw, Indiana.

Advisors' Opinion:

• [By Sean Williams]

  What: Shares of Symmetry Medical (NYSE: SMA  ) , a medical device solutions and surgical instruments manufacturer, dipped as much as 17% after the company updated its second-quarter and full-year financial guidance.

• [By Sean Williams]

  What: Shares of Symmetry Medical (NYSE: SMA  ) , a medical device and surgical instruments maker, fell as much as 19% following a double miss in its first-quarter earnings results.

Hot Low Price Stocks To Buy Right Now: Neurocrine Biosciences Inc.(NBIX)

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, stress-related disorders, pain, tardive dyskinesia, uterine fibroids, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company?s products in clinical development include Elagolix, a Phase II drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; GnRH Antagonists for men?s and women?s health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize Indiplon in Japan; Abbott International Luxembourg S.�r.l. to develop and commercialize elagolix and GnRH antagonists for women?s and men?s health indications; and Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of type II diabetes and other indications. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Advisors' Opinion:

• [By Lauren Pollock]

  Among the companies with shares expected to actively trade in Tuesday’s session are Cyan Inc.(CYNI), Neurocrine Biosciences Inc.(NBIX) and SandRidge Energy Inc.(SD)

5 Best Mid Cap Stocks To Buy Right Now

Despite some volatility lately, performances for stocks have been pretty good to start 2013. The S&P 500 was up double digits through the first six months of the year, even with surging bond yields and concerns over the Fed�� tapering of bond purchases.

Yet while SPY's 14% return is certainly impressive��specially for just six months��his pales in comparison to what investors have seen in a few choice sectors. These market segments have risen roughly twice as much as what we have seen in the S&P 500 in the same time period, suggesting that these have been excellent picks for investors during this six month time frame (read 3 Top Ranked Mid Cap ETFs to Buy Now).

Plus, these sectors appear to be well-positioned in the second half of the year, as the trends that propelled the space higher to begin 2013 are still in place. For this reason, investors might want to take a closer look at the top performing ETFs in the best sectors below, as they could provide for some great ideas to close out 2013 as well.

Best India Stocks To Watch For 2016: Questerre Energy Corp (QEC)

Questerre Energy Corporation (Questerre) is engaged in the exploration for, and the development, production and acquisition of oil and gas projects, particularly shale oil and gas. Questerre holds assets in British Columbia, Alberta, Saskatchewan, Manitoba and Quebec. Questerre has three core areas where it conducts the majority of its activity: Oil Shale Mining, Western Canada and the St. Lawrence Lowlands, Quebec. The Company has a 100% interest in two licenses covering approximately 100,000 acres in the Pasquia Hills area of east central Saskatchewan. The Antler area is approximately 200 kilometers from Regina in southeast Saskatchewan. The Vulcan area in Southern Alberta is prospective for natural gas and oil in multiple horizons. The Lowlands are situated in Quebec south of the St. Lawrence River between Montreal and Quebec City. As at December 31, 2011, the Company had an interest in 98 gross (55.2 net) producing and 40 gross (17.8 net) non-producing oil and natural gas. Advisors' Opinion:

• [By James E. Brumley]

  What do Questerre Energy Corp. (TSE:QEC) and Crescent Point Energy Corp. (TSE:CPG) know about oil in Saskatchewan that Centor Energy Inc. (OTCBB:CNTO) doesn't? Absolutely nothing. All three companies know there's oil in the southern part of the Canadian province, and they know exactly how to go get it. The only difference between QEC, CPG, and CNTO is, Questerre Energy and Crescent Point Energy are further along the development of their operations there than Centor Energy.

5 Best Mid Cap Stocks To Buy Right Now: Stanley Furniture Company Inc.(STLY)

Stanley Furniture Company, Inc., together with its subsidiaries, designs, manufactures, and imports wood furniture products for the residential market. It offers a line of adult furniture products comprising dining, bedroom, home office, home entertainment, and accent items under the Stanley Furniture brand name; and children?s furniture product line under the brand name of Young America. The company provides its products under various design categories, including traditional, continental, contemporary, transitional, and cottage designs. Stanley Furniture Company, Inc. sells its furniture products through independent sales representatives to independent furniture stores, interior designers, smaller specialty retailers, regional furniture chains, buying clubs, and e-tailers in the United States. Stanley Furniture Company, Inc. was founded in 1924 and is based in High Point, North Carolina.

Advisors' Opinion:

• [By Tom Bemis]

  Few major companies are reporting after Monday�� bell. Results are expected from Destiny Media Technologies (DSNY) �, Stanley Furniture Co. (STLY) � and Peregrine Pharmaceuticals. (PPHM) �.

5 Best Mid Cap Stocks To Buy Right Now: First Trust Ise Global Engineering And Construction Index Fund (FLM)

First Trust ISE Global Engineering and Construction Index Fund (the Fund) seeks investment results that correspond generally to the price and yield of an equity index called the ISE Global Engineering and Construction Index (the Index). The Fund is a series of the First Trust Exchange-Traded Fund II, an investment company and an exchange-traded index fund. The Index is developed and owned by the International Securities Exchange, LLC (ISE or Index Provider), in consultation with Standard & Poor's, a Division of The McGraw-Hill Companies, Inc., which calculates and maintains the Index. The Index specifically targets companies that are engaged in civil and capital projects, such as infrastructure, utilities, transportation, telecommunications, commercial, residential and commerce facilities, and whose roles are within the engineering, designing, planning, consulting, project managing and/or constructing of these projects. First Trust Advisors L.P. is the investment adviser for the Fund. Advisors' Opinion:

• [By John Udovich]

  Mid cap infrastructure construction stock Chicago Bridge & Iron Company N.V. (NYSE: CBI) fell 7.23% after being trashed in an article by an apparent�short seller posted on Seeking Alpha, meaning its worth taking a closer look at the stock along with the performance of potential benchmarks like Jacobs Engineering Group Inc (NYSE: JEC), KBR, Inc (NYSE: KBR) and First Trust ISE Global Engineering and Construction Index Fund ETF (NYSEARCA: FLM).

• [By John Udovich]

  Small cap building materials stock NCI Building Systems Inc (NYSE: NCS) fell yesterday after announcing a share offering plus its investors have (so-far) missed out on any ��ecovery��in construction���meaning it might be time to take a closer look at the stock along with potential performance benchmarks like the PowerShares Dynamic Building & Construction ETF (NYSEARCA: PKB) and the First Trust ISE Global Engineering and Construction Index Fund ETF (NYSEARCA: FLM)���both of which have had decent returns in recent years.

5 Best Mid Cap Stocks To Buy Right Now: Biota Pharmaceuticals Inc (BOTA)

Biota Pharmaceuticals, Inc., formerly Nabi Biopharmaceuticals, incorporated on March 14, 1969, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza. Biota developed the neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. The Company�� researches include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir, is approved for marketing in Japan.

The Company�� products include Zanamivir, Inavi, Phoslyra, BioStar OIA FLU and BioStar OIA FLU A/B. Zanamivir is a neuraminidase inhibitor for the treatment and prophylaxis of influenza marketed as Relenza by GlaxoSmithKline. Inavi (laninamivir) is a neuraminidase inhibitor marketed by Daiichi Sankyo in Japan. Phoslyra is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD). BioStar OIA FLU and BioStar OIA FLU A/B are influenza diagnostic tests, which are marketed by Inverness Medical as part of their BioStar product range.

Relenza is delivered directly to the primary site of infection on the lungs, using a Disk Inhaler device. Relenza is approved in over 50 countries for the treatment of influenza, including in the United States, the European Union, Japan and Australia. Relenza is also approved for use as a preventative (prophylactic) treatment against influenza. Inavir is approved for sale in Japan for the treatment of influenza in adults and children. Daiichi Sankyo has applied to sell Inavir in Japan for the prevention of influenza.

PhosLo and Phoslyra are different dose forms of calcium acetate; a phosphate binder approved in multiple countries for the control of hyperphosphatemia (high serum phosphate) in patients with end stage renal disease (ESRD). PhosLo and Pho! slyra were sold to Fresnius Medical Care. Biota, together with its Japanese based partner, Daiichi Sankyo, have developed an inhaled antiviral compounds for influenza, called long acting inhaled neuraminidase inhibitors (LANI). Biota's human rhinovirus (HRV) drug for the prevention and treatment of the causes of the common cold, BTA798, has completed Phase I, Phase IIa and Phase IIb clinical trials.

Advisors' Opinion:

• [By gurujx]

  Biota Pharmaceuticals Inc (BOTA) Reached the 3-year Low of $2.42

  The prices of Biota Pharmaceuticals Inc (BOTA) shares have declined to close to the 3-year low of $2.42, which is 93.3% off the 3-year high of $34.92.

Best Japanese Companies To Own For 2016

Best Japanese Companies To Own For 2016: Sierra Wireless Inc. (SWIR)

Sierra Wireless, Inc., together with its subsidiaries, provides cellular wireless solutions to the machine-to-machine (M2M) and connected device markets in North America, Europe, and the Asia Pacific. The company operates through two segments, Mobile Computing and Machine-to-Machine. It offers AirPrime embedded wireless modules, which are used to wirelessly enable various products and solutions by original equipment manufacturers (OEMs); and AirLink intelligent gateways that are rugged and industrial-grade wireless terminals for M2M and mobile applications to public safety, transportation, field service, energy, industrial, and financial organizations. The companys AirVantage M2M cloud platform provides secure, scalable, and device-to-cloud infrastructure for M2M applications. It also provides professional services to OEM customers during their product development and launch process. The company offers its products to consumer electronics, networking equipment, automotiv e, energy, security, sales and payment, industrial control and monitoring, fleet management, field service, and healthcare industries. It sells its products and solutions through various indirect channels, such as OEMs, wireless operators, distributors, and value-added resellers. Sierra Wireless, Inc. was founded in 1993 and is headquartered in Richmond, Canada.

Advisors' Opinion:

• [By rusticnomad]

  There can't be a superior time to purchase Sierra Wireless (SWIR), the chip creator which is on track to profit from the development in Cisco's (CSCO) Internet of Things.

• [By Chris Neiger]

  Making the connection
  One of the biggest leaders in machine-to-machine communication, or M2M, is Sierra Wireless (NASDAQ: SWIR  ) , a small-cap company that's helping usher in the Internet of Things. The company's 3G-connection module sits in Tesla's Model S sedan and helps the car connect to AT&T'sn! etwork.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/best-japanese-companies-to-own-for-2016.html